Pharma Sector Update For Q2CY15 By Emkay

Tagged: Emkay, Model Portfolio

This topic has 0 replies, 1 voice, and was last updated 9 years, 6 months ago by Vidhi Khanna.

Viewing 1 post (of 1 total)

Author

Posts
July 15, 2015 at 7:04 pm #2218

Vidhi Khanna
Keymaster

Q2 CY15 DMF filings reveal Indian companies have filed for 36% of total filings in Q2 CY15, much lower than the 45% aggregate in 2014 and 47% in 2013. Cumulatively Indian companies filed for 45 molecules in Q2 CY15 compared to 96 in Q1 CY15

Cipla and Alembic file DMF on generics with low competition products –Ambrisentan and Azilsartan respectively. Cipla also filed Albendazole which is off patent but has no generic. Aurobindo, the only Indian filer for injectable for the quarter

Pharmaceuticals Sector Update_100715
Author

Posts

Viewing 1 post (of 1 total)

You must be logged in to reply to this topic.